Modular engineering of Tregs for the treatment of inflammatory and autoimmune diseases 2259867
Analysis of transcriptomic and flow cytometry analyses and a novel hypoimmune approach improves allogeneic cell persistence by preventing T, B, and NK cell mediated rejection support EngTregs as a potent, stable, and versatile cell therapy platform for autoimmune, inflammatory, and ischemic diseases.